Mootral develops innovative carbon reduction solutions for companies and governments. Its first solution is a natural feed supplement that significantly reduces methane emissions from ruminants and is the result of extensive research and development. It is based on a proprietary combination of active compounds from garlic and flavonoids derived from citrus.

ONYA Therapeutics focuses on advancing novel wound treatments combining scientific, commercial and clinical expertise. ONYA owns a pipeline of innovative IP and is advancing its primary asset through Phase II clinical trials for the treatment of exuding diabetic foot ulcers.

Epidermolysis Bullosa is a rare inherited disorder in which the skin is fragile and forms liquid­ filled blisters at sites of rubbing. These blisters can become infected, causing emotional and physical distress to sufferers and reducing their ability to participate in day ­to­day life. Standard­-of­-care management aims to treat the blisters and to prevent them from forming. There are currently no curative treatments.

Mariposa’s approach is showing promise in managing both blister formation and infection in relevant subtypes of this condition.